Arzerra has been studied in people with CLL who failed certain other treatments. In this study, 42 percent of people given Arzerra responded to the medication, as determined by the researchers conducting the study. The median length of response was 6.5 months.
This means that half of the people responded for more than 6.5 months, while half responded fewer than 6.5 months. There was no evidence to indicate the medication reduced symptoms or increased survival in those with CLL.
In studies in previously untreated people who were not good candidates for fludarabine-based treatment, adding Arzerra to chlorambucil almost doubled the length of progression-free survival (the time it takes before the disease gets worse) compared to chlorambucil alone (22.4 months compared to 13.1 months).
When and How to Receive ItSome general considerations to keep in mind during treatment with Arzerra include the following:
- This medication comes in the form of a liquid solution that is given as an intravenous (IV) infusion (a slow injection into a vein) every one to four weeks, with the more frequent doses given earlier in treatment.
- The injection will be given by a healthcare provider in a healthcare setting, such as a doctor's office, clinic, or infusion center. It can take several hours to receive your dose.
- You will be given other medications 30 minutes to 2 hours before your Arzerra dose, to help reduce the chance that you will have a reaction to the infusion.
- For the medication to work properly, it must be used as prescribed. Make sure to keep all of your appointments to receive Arzerra.
Dosing InformationThe dosage your doctor recommends will vary, depending mostly on whether you have tried other CLL medications before or not. As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.
(Click Arzerra Dosage for more information.)